Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following upcoming healthcare conferences in October:

Monday, October 7, 2019Chardan 3rd Annual Genetic Medicines ConferenceLocation: New York, NYTime: 9:00 am ET

Tuesday, October 8, 2019Jefferies Gene Therapy/Editing SummitLocation: New York, NYTime: 8:35 am ET

A live webcast of Intellia’s presentations at the Chardan and Jefferies conferences will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each conference. About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:Lina LiAssociate DirectorInvestor Relations+1 857-706-1612[email protected] 

Media:Jennifer Mound SmoterSenior Vice PresidentExternal Affairs & Communications+1 857-706-1071[email protected]

Source: Intellia Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• NEW NSF-BACKED PROJECT AIMS TO HELP MIDDLE SCHOOLERS DECIDE WHAT TO TRUST IN THE AGE OF AI
• SMM Deal Finder Rebrands as Deeplead, Expanding AI-Powered Outreach to All B2B Sales Teams
• Tenable Uses OpenAI GPT Cyber Models to Help Defenders Inspect Community-Built AI Components